Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058017 | 0.96 | IKBKB (0.57) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL7050462 | 0.88 | CHEK1 (0.54) | IKBKBCHEK1HDAC6ALDH1A1MAPT | |
| SCHEMBL5898669 | 0.87 | IKBKB (0.56) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL5898667 | 0.83 | IKBKB (0.74) | IKBKBJAK2JAK3CHEK1MAP4K4 | |
| SCHEMBL7056317 | 0.82 | IKBKB (0.76) | IKBKBCHEK1HDAC6MEN1KMT2A | |
| SCHEMBL5898642 | 0.82 | IKBKB (0.58) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL7058327 | 0.82 | IKBKB (0.58) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL5898657 | 0.81 | IKBKB (0.76) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL7051641 | 0.81 | IKBKB (0.56) | IKBKBJAK2JAK3CHEK1HDAC6 | |
| SCHEMBL7056909 | 0.80 | IKBKB (0.82) | IKBKBJAK2JAK3CHEK1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030596-A1 | NF-kappaB inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-02-09 | — | — | US | claimed |
| EP-1324759-A4 | NF-G(K)B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-05-12 | — | — | EP | claimed |
| US-20040024047-A1 | Nf-kb inhibitors | SMITHKLINE BEECHMAN CORPORATION | 2004-02-05 | — | — | US | claimed |
| EP-1324759-A2 | NF-G(K)B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2002030353-A2 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1324759-A4 | NF-G(K)B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040024047-A1 | Nf-kb inhibitors | SMITHKLINE BEECHMAN CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1324759-A2 | NF-G(K)B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003029241-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002030353-A2 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030596-A1 | NF-kappaB inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885JAK2 171/4885JAK3 275/4885 |
| US-20040024047-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885JAK2 308/4885JAK3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.